BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
TSMC Posts Record Q1 2026 Profits Driven by Surging AI Chip Demand 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
ATLANTA, April 14, 2016 -- Aviragen Therapeutics, Inc., (NASDAQ:AVIR), formerly Biota Pharmaceuticals, Inc., today announced that Joseph Patti, PhD, President & CEO of Aviragen Therapeutics, will participate in a panel discussion titled, “Notable Emerging Anti-Viral Agents” as part of the FBR & Co. New Prescriptions: Innovation in the Treatment of Diseases and Infections conference.
The panel discussion will take place at 10:30am ET on Wednesday, April 20, 2016 at the JW Marriott Essex House in New York.
About Aviragen Therapeutics, Inc.
Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: These include vapendavir, an oral treatment for human rhinovirus upper (HRV) respiratory infections in moderate-to-severe asthmatics currently being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor that has received Fast Track designation by the U.S. FDA, in Phase 2 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.aviragentherapeutics.com.
Contacts: Mark Colonnese Executive Vice President and Chief Financial Officer Aviragen Therapeutics, Inc. (678) 221-3381 [email protected] Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
